Equities analysts expect Becton, Dickinson and Company (NYSE:BDX) to post sales of $3.13 billion for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Becton, Dickinson and’s earnings, with estimates ranging from $3.09 billion to $3.15 billion. Becton, Dickinson and posted sales of $3.23 billion in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.1%. The firm is expected to announce its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that Becton, Dickinson and will report full year sales of $3.13 billion for the current year, with estimates ranging from $12.02 billion to $12.09 billion. For the next financial year, analysts anticipate that the company will report sales of $12.65 billion per share, with estimates ranging from $12.57 billion to $12.76 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.35 earnings per share.

Several research firms recently issued reports on BDX. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reissued a “buy” rating and issued a $230.00 target price on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and issued a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $195.79.

Becton, Dickinson and (NYSE:BDX) opened at 203.70 on Friday. Becton, Dickinson and has a 52 week low of $161.29 and a 52 week high of $206.63. The stock has a market cap of $46.35 billion, a PE ratio of 58.99 and a beta of 1.06. The company’s 50-day moving average is $200.12 and its 200 day moving average is $190.74.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.43%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

In related news, insider Gary M. Cohen sold 15,044 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total value of $3,015,268.92. Following the completion of the transaction, the insider now directly owns 95,270 shares of the company’s stock, valued at $19,094,966.10. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Nabil Shabshab sold 6,149 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the completion of the transaction, the insider now directly owns 15,648 shares of the company’s stock, valued at $3,157,140.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,605 shares of company stock valued at $9,718,986. 1.40% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of BDX. BlackRock Inc. grew its holdings in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. Koch Industries Inc. grew its holdings in shares of Becton, Dickinson and by 45,268.7% in the second quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after purchasing an additional 1,395,182 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC purchased a new position in shares of Becton, Dickinson and in the second quarter valued at $225,164,000. Finally, Janus Henderson Group PLC grew its holdings in shares of Becton, Dickinson and by 1,265.9% in the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after purchasing an additional 1,122,191 shares in the last quarter. 87.42% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/10/becton-dickinson-and-company-bdx-expected-to-announce-quarterly-sales-of-3-13-billion.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.